This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 18 print issues and online access
$259.00 per year
only $14.39 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Reference
Heier JS, Khanani AM, Quezada Ruiz C, Basu K, Ferrone PJ, Brittain C, et al. Efficacy, durability, and safety of intravitreal faricimab up to every 16 weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE): two randomised, double-masked, phase 3, non-inferiority trials. Lancet. 2022;399:729–40. https://doi.org/10.1016/S0140-6736(22)00010-1.
Author information
Authors and Affiliations
Contributions
All authors equally contributed to the conceptualisation and creation of the visual abstract.
Corresponding author
Ethics declarations
Competing interests
SS reported receiving financial support from AbbVie, Amgen, Apellis, Bayer, Biogen, Boehringer Ingelheim, Novartis, Eyebiotech, Eyepoint Pharmaceuticals, Janssen Pharmaceuticals, Nova Nordisk, Optos, Ocular Therapeutics, Kriya Therapeutics, OcuTerra, Roche, Stealth Biotherapeutics, Sanofi. SS is Editor in Chief of Eye. NW declares no conflict of interest.
Additional information
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Wijesingha, N., Sivaprasad, S. Infographic: Efficacy, durability, and safety of intravitreal faricimab up to every 16 weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE). Eye (2023). https://doi.org/10.1038/s41433-023-02867-4
Received:
Revised:
Accepted:
Published:
DOI: https://doi.org/10.1038/s41433-023-02867-4